Report – Inter Milan Set Hakan Calhanoglu Asking Price As Key Step Toward Securing Suitable Replacement
Report – Inter Milan Set Hakan Calhanoglu Asking Price As Key Step Toward Securing Suitable Replacement
Inter Milan are reluctant to let Hakan Calhanoglu join Galatasaray and will only do that on their own terms.
Per Tuttosport via FCInterNews, it will take around €25 million to persuade the Nerazzurri to give the green light.
Advertisement
Galatasaray's interest in Hakan Calhanoglu is genuine.
Furthermore, the 31-year-old seems inclined to accept the Turkish heavyweights' contract proposal.
Indeed, Okan Buruk's charges are willing to offer him a substantial pay rise to convince him to return to Turkey.
Calhanoglu earns around €6.5m net per season at the San Siro.
However, his wages would hit a €10m landmark at Rams Park.
Inter Milan Name Hakan Calhanoglu Price Tag Amid Galatasaray Rumors
MILAN, ITALY – MARCH 08: Hakan Calhanoglu of FC Internazionale celebrates after scoring their team's second goal during the Serie A match between FC Internazionale and AC Monza at Stadio Giuseppe Meazza on March 08, 2025 in Milan, Italy. (Photo by)
While Galatasaray are ready to hand Calhanoglu a substantial contract, they won't break the bank to strike a deal with Inter.
Indeed, relying on the player's will to join, they'd put forward a meager €15m bid.
Advertisement
Yet, that's well short of Inter's demands.
With the ex-AC Milan midfielder ready to pack his bags, Beppe Marotta is scouring the market for replacements.
Lazio's Nicolo Rovella tops Marotta's shortlist.
Meanwhile, Atalanta's Ederson and Torino's Samuele Ricci are other profiles carefully examined by the Nerazzurri chief.
However, they all command significant price tags.
Therefore, Inter won't let Calhanoglu leave without a suitable financial return.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Gian Piero Gasperini's Roma scour market for 'new Lookman'
Gian Piero Gasperini has been among the best coaches in Serie A over the last decade and this time around he has ended a long stint at Atalanta to go to Roma. As he begins to model a side like the one at Atalanta, the most difficult task is to find a like-for-like replacement for Ademola Lookman. Lookman, 27, was the cornerstone of Gasperini's Atalanta over the last two seasons, contributing to 52 goals in that time span. The challenge is not only to find that output but also his direct threat from out wide. It's worth noting that Lookman himself is reportedly on the market but it is expected that he will be looking at a bigger club, potentially abroad. Advertisement As per Roma have made preliminary shortlist of two players for this role – Igor Paixao from Feyenoord and Abde Ezzalzouli from Real Betis. While neither player is currently at the same level as Lookman, Gasperini's track record with attacking players and it is the Italian who finally got the Nigerian playing at his best. Paixao is expected to cost around €25-30m and Napoli were interested too while Betis will demand €20m for Abde with fellow Serie A club Como also closely monitoring him. Kaulik Mitra | GIFN
Boston Globe
an hour ago
- Boston Globe
Harvard professor turns to private equity to counter Trump research cuts
Under the deal announced Monday, İş Private Equity, a Turkish firm, has committed $39 million to a laboratory run by Gökhan Hotamışlıgil, a professor of genetics and metabolism at the T.H. Chan School of Public Health. The firm, which is a branch of Turkey's İşbank Group, also plans to invest an undisclosed amount of money in any drug candidates that come out of Hotamışlıgil's laboratory and are moved into a new biotech called Enlila. It's a relatively modest deal, in the scope of investment banking. But the collaboration provides much-needed capital at a time when the model for funding scientific research has been thrown into chaos. Advertisement In the first six months of the Trump administration, government officials terminated at least Advertisement In all, Plans for the İş Private Equity collaboration pre-date the Trump administration's science grant retrenchment. Talks began last year, when Hotamışlıgil traveled to Turkey — where he was born and attended university — for a symposium celebrating İşbank Group's centennial. The event was filled with Nobel laureates, entrepreneurs, and others discussing the future of Turkey. Hotamışlıgil gave a presentation at the event detailing his experience as a scientist and his decades-long work exploring fatty acid binding proteins, or FABPs. This hormone is produced in fat cells and secreted into the blood, where it interacts with proteins to form a substance called fabkin. Elevated levels of fabkin are linked to obesity, The presentation caught the attention of İşbank's chief executive. Financing scientific research has always been a challenge, as Hotamışlıgil detailed to the İşbank Group event crowd. It's not easy to explore scientific unknowns while scrounging up grants and other capital. 'In the past, we were complaining about the principles of funding, which overwhelmingly tilted toward more conservative, more guaranteed outcomes… Then, suddenly, there was no funding,' Hotamışlıgil told STAT. Even now, Hotamışlıgil said he is shocked that a country like the U.S. would pull back its scientific financing so drastically, given how much success it's lent to large corporations and research institutions that elicit international envy. Advertisement The federal cuts have plunged many Chan School staff and faculty into cycles of grief and anger, said Amanda Spickard, the associate dean for research strategy and external affairs. They're now emerging from the daze to brainstorm new ways of replacing lost research dollars. In a letter sent out last week, the school's dean of faculty, Andrea Baccarelli, laid out an initial slate of strategies for replacing lost funding, including asking corporate partners to make $100,000 gifts to support Ph.D. students and post-doctorate fellows. The idea has been well-received by executives in need of highly trained employees, said Sarah Branstrator, managing director of academic strategy and research partnerships at the Chan School. School officials are also hopeful that the İşbank collaboration could be the first of multiple privately financed labs. There have been isolated examples in which investment firms have financed specific university centers or research projects, often for preferential access to any new scientific innovations that come out of the laboratories. Just across the Charles River from the Chan School, Harvard's Wyss Institute has spent the last five years working with an affiliate of the science-focused VC firm Northpond Ventures. Northpond initially committed $12 million to the alliance in 2020, and has made New York investment firm Deerfield Management has been much more aggressive in funding early-stage research. It has committed around $390 million to collaborations with Advertisement Hotamışlıgil's lab may be a unique case, as metabolism has become a hot area of drug development, thanks to the success of Eli Lilly and Novo Nordisk's GLP-1 weight loss medications. Obesity-focused startups are still raking in Meanwhile, other areas of public health research, like infectious diseases and vaccines, are a 'It is probably too optimistic to say that government funding could completely be replaced. Government funding is really crucial to keep science as its engine. Having said that, for the school faculty, there are incredible opportunities, in my view,' Hotamışlıgil said. '[This] gives some hope that there's also some alternative ways that we can support science.'
Yahoo
an hour ago
- Yahoo
Shipping Billionaire's $170M Power Play: Why Caravel Just Took Over Pacific Basin
Harry Banga's Caravel Group is making waves in the dry bulk shipping worldwithout saying much. As of June 12, Caravel now owns over 672 million shares of Pacific Basin (PCFBY), pushing its stake to just above 13%. That's a fast climb from the 7.5% disclosed in late March, and it makes Caravel the company's largest shareholder. With Pacific Basin valued around $1.3 billion and posting $2.6 billion in adjusted revenue last year, this is no passive holding. This is a calculated, high-conviction bet on global commodity demand. Warning! GuruFocus has detected 4 Warning Sign with PCFBY. Caravel, founded by Banga in 2013 after decades in commodity trading, knows this space inside out. The firm operates or manages over 650 vessels across its shipping and asset management arms, giving it rare visibility into freight flows and pricing power. A Caravel spokesperson told Bloomberg the stake reflects the company's confidence in Pacific Basin's future, suggesting this isn't a short-term tradeit's a positioning move for the next cycle. With bulk shipping often overlooked during tech-dominated rallies, this type of insider conviction may signal opportunity brewing beneath the surface. And this isn't the Banga family's only strategic move. They're also among the top three shareholders in FSN E-Commerce Ventures, parent of Indian beauty giant Nykaa, which pulled off a $715 million IPO in 2021. Harry's son, Angad BangaCaravel's COOhas been active on the venture side too, co-founding Sorin Investments with ex-KKR India chief Sanjay Nayar. From shipping lanes to startup land, this family isn't chasing headlines. They're quietly building exposure across Asia's next growth curve. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
